The challenge of deciding which drugs are approved for medical treatment and which are not is a combination of ethical reasoning, cost and benefit analysis and medical knowledge.
Depression is the leading cause of disability in the world, caused by deficiency in neurotransmitters - serotonin and norepinephrine. PTSD is caused by an individual experiencing such a traumatic incident, that the memory of it interferes continuously with their life. Both for depression and PTSD the usual cure is treatment with selective serotonin reuptake inhibitors (SSRI), where serotonin and other neurotransmitters are continuously hindered in getting reabsorbed into the synapse. Chronic pain is an aftermath of an extensive injury, typical treatment for stronger pain is opioids such as morphine or codeine.
LSD has shown potential in treating depression by blocking the default mode network (DMN) and thereby relaxing the hyperactivity of it. MDMA has the capability, by pushing active serotonin into the system, to let the patient open up psychologically to to therapy. An alternative to chronic pain is cannabis with its derivatives, which interacts with pain receptors and increases one’s pain threshold, making chronic pain less impactful on one’s daily life.
The three cases are weighted through consequential and deontological ethical views; in all views the answer to legalizing the three drugs, LSD, MDMA and cannabis, for experimental medical research is yes.
|Uddannelser||Kemi, (Bachelor/kandidatuddannelse) BachelorMiljøbiologi, (Bachelor/kandidatuddannelse) BachelorMolekylærbiologi, (Bachelor/kandidatuddannelse) Bachelor|
|Udgivelsesdato||19 dec. 2017|
|Vejledere||Lauren Paige Seaby|